NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved for marketing Qiagen's therascreen EGFR test as a companion diagnostic test for Boehringer Ingelheim's new targeted treatment for metastatic non-small cell lung cancer, Qiagen said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.